System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Clément Morgat is an expert in Nuclear medicine at Centre Hospitalier Universitaire de Bordeaux (France). Clément Morgat has authored 72 publications, the most recent in 2026, and is an investigator in 4 clinical trials. SLR score: 357 (community average: 125). How the SLR is computed.

LeadR Profile

Clément Morgat Centre Hospitalier Universitaire de Bordeaux France
357 ScienceLeadR Reputation 357

Unlock

Register Login
Network Map

Nuclear medicine

Subspecialties: Urology - Neurology - Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2013 - 2026
Source: PubMed

Institut de Neurosciences Cognitives et Intégratives d’Aquitaine

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 72

Citations

Citations: 835 1st author: 16 Last author: 24 Unique author: 1

Main journals

J Nucl Med 11
MED NUCL 7
EJNMMI Res 5
Neurology 4
Eur J Nucl Med Mol Imaging 3

Best Journals

Lancet Oncol 2
Eur Heart J 1
J Clin Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Re: Sobia Khan, Nathan Papa, Andrew Kneebone, et al. Prospective Comparison of 64Copper [ 64Cu]SAR-bisPSMA vs 68Gallium [ 68Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial). Eur Urol 2026;89:512-20.
PMID 42829270 — urology, neoplasms, prostate, positron emission tomography computed tomography, prostatic neoplasms, prostatectomy		Eur Urol20260
Sleep's influence on susceptibility to motion sickness in parabolic flights and virtual reality: An exploratory study.
PMID 42576478 — virtual reality, sleep, motion sickness, hydrocortisone		J Vestib Res20260
Terbium-161 might be superior to lutetium-177 for oligometastases.
PMID 42372749 — neoplasms		Lancet Oncol Top journal20260
Fully GMP-complient radiosynthesis of [ 161Tb]Tb-PSMA-1 using the miniAiO synthesizer for clinical translation.
PMID 42334711 — buffers, neoplasms, prostate, acetates, prostatic neoplasms, ethanol, temperature		EJNMMI Radiopharm Chem20260
Prospective head-to-head comparison of [ 68Ga]Ga-RM2 PET/CT and [ 68Ga]Ga-PSMA-617 PET/CT in newly diagnosed patients with intermediate-risk localized prostate cancer.
PMID 41656418 — neoplasms, prostate, positron emission tomography computed tomography, prostatic neoplasms, nuclear medicine		Eur J Nucl Med Mol Imaging20260

Clinical Studies 4

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 2
N/A 1
Phase 2 1

By status:

Completed 3
Recruiting 1

By type:

Interventional 3
Observational 1

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 0
multicentricup10 3

Main Topics

Cohort/Consortium Investigators 4

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS